Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy.

Clinical and translational radiation oncology·2026
Same author

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026
Same author

Outcomes of critically ill patients with newly diagnosed Burkitt's lymphoma: a monocentric retrospective study.

Annals of intensive care·2026
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026

Related Experiment Video

Updated: Mar 24, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

991

Optimizing therapy for nodal marginal zone lymphoma.

Catherine Thieblemont1, Thierry Molina2, Frédéric Davi3

  • 1Hémato-Oncologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Sorbonne Paris Cité, Université Paris Diderot, Paris, France; Sorbonne Paris Cité, EA7324, Paris Descartes Université, Paris, France;

Blood
|March 19, 2016
PubMed
Summary
This summary is machine-generated.

Nodal marginal zone lymphoma (NMZL) is an incurable B-cell lymphoma. Current treatments are nonspecific, but research into deregulated pathways offers hope for personalized therapies.

More Related Videos

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

2.9K

Related Experiment Videos

Last Updated: Mar 24, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

991
Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

2.9K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Nodal marginal zone lymphoma (NMZL) is a rare, indolent B-cell lymphoma identified in the last two decades.
  • NMZL remains incurable, with slow therapeutic progress due to small patient numbers and treatment heterogeneity.
  • Standard-of-care treatment for NMZL is currently nonspecific.

Purpose of the Study:

  • To review current treatments for adult NMZL patients.
  • To describe biological research into key axes of agents under development for NMZL.
  • To project future personalized treatment approaches for NMZL.

Main Methods:

  • Review of routinely used treatments, primarily immunochemotherapy.
  • Description of biological research based on gene profiling and genome-wide sequencing.
  • Examination of deregulated pathways specific to NMZL tumors.

Main Results:

  • Key deregulated pathways in NMZL include B-cell receptor, JAK/STAT, NF-κB, NOTCH, and Toll-like receptor signaling.
  • Intracellular processes like cell cycle, chromatin remodeling, and transcriptional regulation are implicated.
  • Immune escape mechanisms, including T-cell-mediated tumor surveillance, are identified.

Conclusions:

  • Novel therapeutic agents are being developed based on identified NMZL-specific pathways.
  • Understanding these pathways is crucial for advancing personalized treatment strategies.
  • Future research aims to evolve the field towards efficient, personalized NMZL treatment.